Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 11/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | ESR1 | P03372 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.49 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | GRM5 | P41594 | 4/20 | 0.49 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | TACR3 | P29371 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL930063 | 0.90 | ESR2 (0.64) | P2RX7ALDH1A1ESR1POLBESR2 | |
| SCHEMBL3820359 | 0.86 | P2RX7 (0.55) | P2RX7PARP1TACR3 | |
| SCHEMBL928735 | 0.85 | GRM5 (0.47) | P2RX7ALDH1A1ESR1POLBESR2 | |
| SCHEMBL928669 | 0.84 | P2RX7 (0.49) | P2RX7GRM5TACR3 | |
| SCHEMBL927851 | 0.83 | GRM5 (0.51) | P2RX7ALDH1A1TDP1GRM5TACR3 | |
| SCHEMBL929581 | 0.83 | ALDH1A1 (0.52) | ALDH1A1ESR1POLBESR2CTDSP1 | |
| SCHEMBL930001 | 0.83 | TACR3 (0.63) | P2RX7TACR3 | |
| SCHEMBL930089 | 0.83 | P2RX7 (0.54) | P2RX7GRM5TACR3 | |
| SCHEMBL928104 | 0.82 | GRM5 (0.51) | P2RX7GRM5TACR3 | |
| SCHEMBL928854 | 0.82 | GRM5 (0.56) | P2RX7ALDH1A1ESR1POLBESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2085398-A1 | Pyrazolopyrimidines, a process for their preparation and their use as medicine | Merz Pharma GmbH & Co. KGaA (DE) | 2009-08-05 | — | — | EP | claimed |
| US-20110003820-A1 | PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | MERZ PHARMA GMBH & CO. KGAA (DE) | 2011-01-06 | — | — | US | disclosed |
| EP-2247590-A1 | PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | Merz Pharma GmbH & Co. KGaA (DE) | 2010-11-10 | — | — | EP | disclosed |
| WO-2009095254-A1 | PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | MERZ PHARMA GMBH & CO. KGAA (DE) | 2009-08-06 | — | — | WO | disclosed |
| EP-2085398-A1 | Pyrazolopyrimidines, a process for their preparation and their use as medicine | Merz Pharma GmbH & Co. KGaA (DE) | 2009-08-05 | — | — | EP | disclosed |
| EP-2085398-A1 | Pyrazolopyrimidines, a process for their preparation and their use as medicine | Merz Pharma GmbH & Co. KGaA (DE) | 2009-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003820-A1 | PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | GRM5, GRIK5, GRK5 | P2RX7 71/4885ALDH1A1 2888/4885ESR1 3004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.